Literature DB >> 21251607

Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity.

Yuhui Huang1, Matija Snuderl, Rakesh K Jain.   

Abstract

Vascular normalization is an emerging concept in cancer treatment. In this issue of Cancer Cell, Rolny et al. show that histidine-rich glycoprotein normalizes tumor vessels and promotes antitumor immunity by polarizing tumor-associated macrophages, leading to decreased tumor growth and metastasis. Placental Growth Factor deletion in macrophages phenocopies many of these effects. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Year:  2011        PMID： 21251607      PMCID： PMC3037265          DOI： 10.1016/j.ccr.2011.01.005

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

Review 1.  Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.

Authors:  R K Jain
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

Review 2.  Macrophages, innate immunity and cancer: balance, tolerance, and diversity.

Authors:  Alberto Mantovani; Antonio Sica
Journal:  Curr Opin Immunol       Date:  2010-02-09       Impact factor: 7.486

3.  HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF.

Authors:  Charlotte Rolny; Massimiliano Mazzone; Sònia Tugues; Damya Laoui; Irja Johansson; Cathy Coulon; Mario Leonardo Squadrito; Inmaculada Segura; Xiujuan Li; Ellen Knevels; Sandra Costa; Stefan Vinckier; Tom Dresselaer; Peter Åkerud; Maria De Mol; Henriikka Salomäki; Mia Phillipson; Sabine Wyns; Erik Larsson; Ian Buysschaert; Johan Botling; Uwe Himmelreich; Jo A Van Ginderachter; Michele De Palma; Mieke Dewerchin; Lena Claesson-Welsh; Peter Carmeliet
Journal:  Cancer Cell       Date:  2011-01-06       Impact factor: 31.743

Review 4.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

5.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

Authors:  Frank Winkler; Sergey V Kozin; Ricky T Tong; Sung-Suk Chae; Michael F Booth; Igor Garkavtsev; Lei Xu; Daniel J Hicklin; Dai Fukumura; Emmanuelle di Tomaso; Lance L Munn; Rakesh K Jain
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

6.  FcRgamma activation regulates inflammation-associated squamous carcinogenesis.

Authors:  Pauline Andreu; Magnus Johansson; Nesrine I Affara; Ferdinando Pucci; Tingting Tan; Simon Junankar; Lidiya Korets; Julia Lam; David Tawfik; David G DeNardo; Luigi Naldini; Karin E de Visser; Michele De Palma; Lisa M Coussens
Journal:  Cancer Cell       Date:  2010-02-04       Impact factor: 31.743

7.  Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.

Authors:  Christian Fischer; Bart Jonckx; Massimiliano Mazzone; Serena Zacchigna; Sonja Loges; Lucia Pattarini; Emmanuel Chorianopoulos; Laurens Liesenborghs; Marta Koch; Maria De Mol; Monica Autiero; Sabine Wyns; Stephane Plaisance; Lieve Moons; Nico van Rooijen; Mauro Giacca; Jean-Marie Stassen; Mieke Dewerchin; Desire Collen; Peter Carmeliet
Journal:  Cell       Date:  2007-11-02       Impact factor: 41.582

8.  Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization.

Authors:  Massimiliano Mazzone; Daniela Dettori; Rodrigo Leite de Oliveira; Sonja Loges; Thomas Schmidt; Bart Jonckx; Ya-Min Tian; Anthony A Lanahan; Patrick Pollard; Carmen Ruiz de Almodovar; Frederik De Smet; Stefan Vinckier; Julián Aragonés; Koen Debackere; Aernout Luttun; Sabine Wyns; Benedicte Jordan; Alberto Pisacane; Bernard Gallez; Maria Grazia Lampugnani; Elisabetta Dejana; Michael Simons; Peter Ratcliffe; Patrick Maxwell; Peter Carmeliet
Journal:  Cell       Date:  2009-02-12       Impact factor: 41.582

Review 9.  Histidine-rich glycoprotein modulation of immune/autoimmune, vascular, and coagulation systems.

Authors:  Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

10.  Vascular normalization in Rgs5-deficient tumours promotes immune destruction.

Authors:  Juliana Hamzah; Manfred Jugold; Fabian Kiessling; Paul Rigby; Mitali Manzur; Hugo H Marti; Tamer Rabie; Sylvia Kaden; Hermann-Josef Gröne; Günter J Hämmerling; Bernd Arnold; Ruth Ganss
Journal:  Nature       Date:  2008-04-16       Impact factor: 49.962
  10 in total
  34 in total

Review 1.  Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

Authors:  Shom Goel; Andus Hon-Kit Wong; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

Review 2.  A review on myricetin as a potential therapeutic candidate for cancer prevention.

Authors:  Nazia Afroze; Sreepoorna Pramodh; Arif Hussain; Madiha Waleed; Kajal Vakharia
Journal:  3 Biotech       Date:  2020-04-24       Impact factor: 2.406

3.  Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.

Authors:  Norbert Galldiks; Marion Rapp; Gabriele Stoffels; Gereon R Fink; Nadim J Shah; Heinz H Coenen; Michael Sabel; Karl-Josef Langen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-29       Impact factor: 9.236

4.  Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.

Authors:  A Gregory Sorensen; Kyrre E Emblem; Pavlina Polaskova; Dominique Jennings; Heisoog Kim; Marek Ancukiewicz; Meiyun Wang; Patrick Y Wen; Percy Ivy; Tracy T Batchelor; Rakesh K Jain
Journal:  Cancer Res       Date:  2011-11-29       Impact factor: 12.701

5.  CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.

Authors:  Yunching Chen; Rakesh R Ramjiawan; Thomas Reiberger; Mei R Ng; Tai Hato; Yuhui Huang; Hiroki Ochiai; Shuji Kitahara; Elizabeth C Unan; Tejaswini P Reddy; Christopher Fan; Peigen Huang; Nabeel Bardeesy; Andrew X Zhu; Rakesh K Jain; Dan G Duda
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

6.  Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.

Authors:  Christine Lu-Emerson; Matija Snuderl; Nathaniel D Kirkpatrick; Jermaine Goveia; Christian Davidson; Yuhui Huang; Lars Riedemann; Jennie Taylor; Percy Ivy; Dan G Duda; Marek Ancukiewicz; Scott R Plotkin; Andrew S Chi; Elizabeth R Gerstner; April F Eichler; Jorg Dietrich; Anat O Stemmer-Rachamimov; Tracy T Batchelor; Rakesh K Jain
Journal:  Neuro Oncol       Date:  2013-07-04       Impact factor: 12.300

7.  Experimental and computational analyses reveal dynamics of tumor vessel cooption and optimal treatment strategies.

Authors:  Chrysovalantis Voutouri; Nathaniel D Kirkpatrick; Euiheon Chung; Fotios Mpekris; James W Baish; Lance L Munn; Dai Fukumura; Triantafyllos Stylianopoulos; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-30       Impact factor: 11.205

Review 8.  Cancer and inflammation.

Authors:  Lance L Munn
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2016-12-12

Review 9.  Vascular normalization as an emerging strategy to enhance cancer immunotherapy.

Authors:  Yuhui Huang; Shom Goel; Dan G Duda; Dai Fukumura; Rakesh K Jain
Journal:  Cancer Res       Date:  2013-02-25       Impact factor: 12.701

10.  Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy.

Authors:  Yuhui Huang; Jianping Yuan; Elda Righi; Walid S Kamoun; Marek Ancukiewicz; Jean Nezivar; Michael Santosuosso; John D Martin; Margaret R Martin; Fabrizio Vianello; Pierre Leblanc; Lance L Munn; Peigen Huang; Dan G Duda; Dai Fukumura; Rakesh K Jain; Mark C Poznansky
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.